All Resources
eBook: How to Get More Molecules to the Clinic Faster with Automated Cell Line Development
Learn how our Opto CLD workflow can help remove the bottleneck from traditional cell line development.
Webinar: Bring Product Quality Assessment into Early Clone Selection with Opto™ Cell Line Development
CHO cell line selection represents a painful bottleneck in biotherapeutic development, particularly for complex molecules like bispecifics. At BPI Europe Digital Week 2021, Renee Tobias discussed how the Opto™ CLD workflow on the Beacon® system can help through accelerating early CLD by integrating high throughput cell sorting, cloning, culture, productivity, growth, and product quality assays into a single, 5-day automated process.
Webinar: Abveris on Lessons Learned from 2+ Years of Discovering Functional Antibodies on the Beacon
At PEGS EU 2021, Abveris CEO Tracey Mullen shared a few important lessons learned through using the Beacon system for antibody discovery. She discussed how the Berkeley Lights Platform has enabled Abveris to focus on deeply screening their antibodies upstream and only pulling forward the most qualified and functionally relevant antibodies for re-expression.
App Note: Discover Lead Molecules Against Difficult Targets in 1 Week with Opto™ Plasma B Discovery 4.0
Find out how the Opto Plasma B Discovery 4.0 workflow can be used to access broad plasma cell diversity, rapidly down-select lead candidates with functional profiling, and sequence and re-express >1,000 functionally characterized antibodies in 1 week.
Webinar: Opto™ Plasma B Discovery 4.0 Fireside Chat
Join members of our Opto Plasma B Discovery 4.0 development team for a panel discussion about our latest antibody discovery workflow.
Customer Spotlight: Amgen on the Berkeley Lights Platform
Philip Tagari, VP Therapeutic Discovery, Amgen, discusses how the Berkeley Lights’ platform has transformed the way Amgen approaches antibody discovery and cell line development.
Brochure: Get to the Clinic First with Best-In-Class Antibody Therapeutics
Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows Pharma to succeed against difficult targets and deliver best-in-class antibody therapeutics.
Brochure: Lead Molecules Against Any Target. At Record Pace.
Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows CROs to scale their business and rapidly deliver lead molecules even against difficult targets.
Webinar: Rapid Discovery of Functional Antibodies for SARS-CoV-2
Dr. Robert Carnahan, Ph.D., discusses how the Beacon system helped enable the rapid discovery functional antibodies against SARS-CoV-2.
Datasheet: Adherent Cell Kit
Learn more about how the Adherent Cell Kit enables the isolation, growth, monitoring and recovery of adherent cells on the Beacon® and Lightning™ Optofluidic systems.
App Note: Bring Product Quality Assessment into Early Clone Selection with the Opto™ Assure Aggregation Assay
Read this application note to learn more about how to get early, multi-parameter assessment of clones with the Opto Assure assay series.
Customer Spotlight: Genovac on Antibody Discovery
Find out how Genovac is delivering 10-fold more lead candidates against difficult targets.
Brochure: Get to Market Faster with the Opto CLD Workflow
Find out how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development to let BioPharma get more molecules to the clinic faster.
Brochure: Increase CDMO Revenue with the Opto CLD Workflow
Find our how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development and allows CDMOs to scale operations and drive new business.
Webinar: Leveraging Innovative Technologies to Accelerate Biologics Development
At the 2021 BPS EU virtual conference, Beacon user Joaquina Mascarenhas, PhD, at Thermo Fisher Scientific shares how the Berkeley Lights Platform enables their cell line development to move at world class speed and select the best clones.
Webinar: Characterizing T Cell Functionality on the Berkeley Lights Lightning Platform
Hear from Dr. Anthony Zamora, Assistant Professor at Medical College of Wisconsin, discusses how the Lightning system enables rapid functional characterization of T cells and allows for thousands of single cells to be isolated, cultured, assayed, and exported for further analysis.
Webinar: Looking to the Future: What’s next in Antibody Therapeutics
At the 2021 AE&T EU conference, Tracey Mullens, CEO of Abveris, and Brian Walters, CEO of Genovac, joined John Proctor, SVP Antibody Therapeutics, for a discussion about the evolving landscape of antibody therapeutics, the technologies they have turned to address today’s complex targets, and how they are preparing for tomorrow’s challenges.
Webinar: Accelerating Discovery and Development of Antibody Therapeutics
Hear from BLI experts Renee Tobias and Anupam Singhal about the unique benefits to leveraging a single platform for both the identification of promising candidates and the production of leading therapeutic molecules.